ECO Animal Health’s interim results highlight continued growth, with Aivlosin® generating strong demand. Sales of the antimicrobial increased 18% and is on track to meet our full year estimate of £53m. EBITDA and EPS increased by 36% and 13% respectively. The balance sheet remains robust (£20.3m net cash at period end) and the interim dividend of 3.2p is 28% higher than last year. H2 has reportedly started well with a strong and growing order book. Our EBITDA forecast is unchanged and we upgrade ....

06 Dec 2017
N+1 Singer - ECO Animal Health Group - Aivlosin® demand continues to grow

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ECO Animal Health Group - Aivlosin® demand continues to grow
ECO Animal Health Group plc (EAH:LON) | 97.5 -1 (-1.0%) | Mkt Cap: 66.0m
- Published:
06 Dec 2017 -
Author:
Sheena Berry -
Pages:
6 -
ECO Animal Health’s interim results highlight continued growth, with Aivlosin® generating strong demand. Sales of the antimicrobial increased 18% and is on track to meet our full year estimate of £53m. EBITDA and EPS increased by 36% and 13% respectively. The balance sheet remains robust (£20.3m net cash at period end) and the interim dividend of 3.2p is 28% higher than last year. H2 has reportedly started well with a strong and growing order book. Our EBITDA forecast is unchanged and we upgrade ....